InvestorsHub Logo
Followers 827
Posts 119503
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Friday, 03/01/2024 2:51:37 PM

Friday, March 01, 2024 2:51:37 PM

Post# of 245
EOLS PR on licensed dermal-filler:

https://finance.yahoo.com/news/evolus-announces-results-european-head-133000744.html

The European Lift study was blinded, randomized, 9 months in duration, and enrolled 45 patients. The study was a split face design, in which each patient received Estyme Lift on one side and the control, Restylane-L, on the other side. Using a validated 5-point scale, the change in Nasolabial Fold (NLF) severity from baseline was measured. The primary endpoint of non-inferiority was met at 4 weeks, with the results favoring Estyme Lift, and at 3 and 6 months, Estyme Lift achieved statistical superiority over Restylane-L.

A head-to-head versus Juvederm Vollure might have been more illuminating.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EOLS News